Search results for " Combination"

showing 10 items of 923 documents

Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation.

1998

Background —This study was performed to analyze the influence of either aspirin, ticlopidine, or their combination on platelet activation and aggregation parameters after stent implantation. Methods and Results —Sixty-one patients with successful implantation of a single Palmaz-Schatz stent in a native coronary artery were randomly assigned to either group A (aspirin 300 mg/d+ticlopidine 2×250 mg/d), group B (ticlopidine 2×250 mg/d), or group C (aspirin 300 mg/d). Platelet activation was evaluated on days 1, 7, and 14 by flow cytometry measurement of expression of CD62p (p-selectin) and the binding of fibrinogen to the platelet surface glycoprotein IIb/IIIa receptor. Platelet aggregation w…

medicine.medical_specialtyTiclopidineTime FactorsPlatelet Aggregationmedicine.medical_treatmentUrologyCoronary DiseasePlatelet Glycoprotein GPIIb-IIIa ComplexFibrinogenPhysiology (medical)MedicineHumansPlateletPlatelet activationTiclopidineAngioplasty Balloon CoronaryAspirinChemotherapyAspirinbusiness.industryStentFibrinogenP-SelectinAnesthesiaPlatelet aggregation inhibitorDrug Therapy CombinationStentsCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugCirculation
researchProduct

The pharmacological rationale for combining muscarinic receptor antagonists and beta-adrenoceptor agonists in the treatment of airway and bladder dis…

2014

Highlights • Muscarinic receptors increase smooth muscle tone in airways and urinary bladder. • β-Adrenoceptors relax smooth muscle tone and oppose muscarinic contraction. • Opposition involves transmitter release, signal transduction and receptor expression. • This supports the combined use of muscarinic antagonists and β-adrenoceptor agonists.

medicine.medical_specialtyUrologyDiseaseMuscarinic AntagonistsPharmacologyArticleβ adrenoceptorchemistry.chemical_compoundInternal medicineReceptors Adrenergic betaMuscarinic acetylcholine receptorDrug DiscoveryMuscarinic acetylcholine receptor M4RAT URINARY-BLADDERMedicineAnimalsHumansCyclic adenosine monophosphateADRENERGIC RELAXATIONLung Diseases ObstructivePROTEIN-KINASE-CReceptorTRACHEAL SMOOTH-MUSCLEPharmacologybusiness.industryUrinary Bladder DiseasesMuscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2ACETYLCHOLINE-RELEASEAdrenergic beta-Agonistsmedicine.diseaseReceptors MuscarinicEndocrinologyNONNEURONAL CHOLINERGIC SYSTEMchemistryGUINEA-PIG TRACHEADrug Therapy CombinationCYCLIC ADENOSINE-MONOPHOSPHATECA2+-ACTIVATED K+ CHANNELAirwaybusinessUrinary bladder diseaseAUTORADIOGRAPHIC VISUALIZATIONAcetylcholinemedicine.drug
researchProduct

The future: critical knowledge about anti-itch therapy.

2005

:  Itch is an extremely frequent and enervating symptom of many diseases. Current anti-itch therapy, which is based almost exclusively on an “immunocentric” viewpoint, is often unsatisfactory. Recent studies show that this symptom is in fact the result of a complex interplay among skin, nervous system, endocrine system, and immune system. This explains the frequent failure of therapeutic strategies focused only on a single factor and suggests the usefulness of a polypharmacologic symptomatic treatment, designed on a case-by-case basis as a result of a multidisciplinary approach. We discuss the perspectives of anti-itch therapy in light of the new pathogenetic and pharmacologic acquisitions.

medicine.medical_specialtybusiness.industryNarcotic AntagonistsPruritusSymptomatic treatmentSingle factorDermatologyGeneral MedicineAntipruriticsMultidisciplinary approachImmunologyNeural PathwaysmedicineHumansDrug Therapy CombinationProtease InhibitorsCapsaicinIntensive care medicinebusinessDermatologic therapy
researchProduct

Glutathione, GlutathioneS-Transferase α and π, and Aldehyde Dehydrogenase Content in Relationship to Drug Resistance in Ovarian Cancer

1997

Glutathione, glutathione S-transferases alpha and pi, and aldehyde dehydrogenase are associated with resistance to carboplatin and/or cyclophosphamide in cell lines. Therefore, we examined whether the expression of these factors in ovarian cancer tissue specimens is associated with resistance of the patients to combination chemotherapy with cyclophosphamide/carboplatin. Ovarian cancer tissue specimens were taken intraoperatively from 139 patients and frozen in liquid nitrogen, and the contents of glutathione S-transferases alpha and pi, total glutathione, and aldehyde dehydrogenase activity were determined. No association between the levels of glutathione S-transferases alpha and pi or alde…

medicine.medical_specialtyendocrine system diseasesCyclophosphamidemedicine.medical_treatmentBlotting WesternAldehyde dehydrogenaseAntineoplastic AgentsOvaryCarboplatinchemistry.chemical_compoundInternal medicineHumansMedicineAntineoplastic Agents AlkylatingCyclophosphamideGlutathione TransferaseNeoplasm StagingOvarian NeoplasmsChemotherapybiologybusiness.industryObstetrics and GynecologyCombination chemotherapyGlutathioneAldehyde DehydrogenasePrognosismedicine.diseaseCombined Modality TherapyGlutathioneDrug Resistance Multiplefemale genital diseases and pregnancy complicationsCarboplatinmedicine.anatomical_structureEndocrinologyOncologychemistryDrug Resistance Neoplasmbiology.proteinCancer researchDrug Therapy CombinationFemaleCisplatinbusinessOvarian cancermedicine.drugGynecologic Oncology
researchProduct

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension deliver…

2018

COPD causes considerable health and economic burden worldwide, with incidence of the disease expected to continue to rise. Inhaled bronchodilators, such as long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs), are central to the maintenance treatment of patients with COPD. Clinical studies have demonstrated that combined LAMA + LABA therapies improve efficacy while retaining a safety profile similar to LAMA or LABA alone. This has led to the development of several LAMA/LABA fixed-dose combination (FDC) therapies, which provide patients with the convenience of two active compounds in a single inhaler. GFF MDI (Bevespi Aerosphere®) is an FDC of glycopyrrolate/formote…

medicine.medical_specialtymedicine.drug_classDrug CompoundingFixed-dose combinationMuscarinic AntagonistsPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineFormoterol FumarateBronchodilatorAdministration InhalationmedicineHumans030212 general & internal medicineIntensive care medicineAdrenergic beta-2 Receptor AgonistsGlycopyrrolateCOPDbiologybusiness.industryInhalerGeneral MedicineLamamedicine.diseasebiology.organism_classificationGlycopyrrolateMetered-dose inhalerBronchodilator AgentsDrug CombinationsTreatment Outcome030228 respiratory systemFormoterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Steroid and vasoactive treatment for acute deafness after attempted hearing preservation acoustic neuroma surgery.

2004

<i>Objective:</i> To investigate whether intravenous steroid and vasoactive therapy in the acute postoperative period improves hearing outcome in patients who develop acute deafness after attempted hearing preservation surgery for acoustic neuroma (AN) through a retrosigmoid or a middle cranial fossa approach. <i>Study Design and Setting:</i> Retrospective controlled study in a tertiary care center. Thirty-six patients who had developed acute deafness after hearing preservation surgery for treatment of an AN were reviewed. Preoperative AAOHNS hearing class was A in 2, B in 2 and D in 32 patients. Twenty-seven patients were treated with prednisolone, hydroxyethyl star…

medicine.medical_specialtymedicine.drug_classHearing lossmedicine.medical_treatmentPrednisoloneVasodilator AgentsAnti-Inflammatory AgentsAcoustic neuromaDeafnessHydroxyethyl Starch DerivativesPostoperative ComplicationsAcoustic neuroma surgeryVasoactiveotorhinolaryngologic diseasesmedicineEvoked Potentials Auditory Brain StemHumansIn patientPentoxifyllineRetrospective StudiesSalvage TherapyHearing preservationChemotherapybusiness.industryNeuroma Acousticmedicine.diseaseSurgeryOtorhinolaryngologyAnesthesiaAcute DiseaseInjections IntravenousCorticosteroidDrug Therapy Combinationmedicine.symptombusinessORL; journal for oto-rhino-laryngology and its related specialties
researchProduct

Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simula…

2020

Omar S Usmani,1 Nicola Scichilone,2 Benjamin Mignot,3 Dennis Belmans,3 Cedric Van Holsbeke,3 Jan De Backer,3 Roberta De Maria,4 Erika Cuoghi,4 Eva Topole,4 George Georges4 1Airway Disease Section, National Heart and Lung Institute, Imperial College, London, UK; 2PROMISE Department of Medicine, University of Palermo, Palermo, Italy; 3FLUIDDA, Kontich, Belgium; 4Chiesi Farmaceutici, SpA, Parma, ItalyCorrespondence: George GeorgesChiesi USA Inc., 175 Regency Woods Place, Ste. 600, Cary, NC 27518, USATel +1 (919) 678 6611 x1536Email george.georges@chiesi.comIntroduction: There is a clear correlation between small airways dysfunction and poor clinical outcomes in patients with chronic obstructiv…

medicine.medical_specialtymedicine.drug_classRespiratory SystemUrologyInternational Journal of Chronic Obstructive Pulmonary DiseaseSettore MED/10 - Malattie Dell'Apparato RespiratoriotomographyDry powder inhalers Inhaled corticosteroid Long-acting beta2 agonist Long-acting muscarinic antagonist Metered dose inhalers Tomography X-ray computedinhaled corticosteroidFluticasone propionatePulmonary Disease Chronic Obstructivechemistry.chemical_compoundFormoterol FumarateBronchodilatorAdministration InhalationmedicineHumanslong-acting muscarinic antagonistComputer SimulationGlycopyrronium bromideRespiratory systemmetered dose inhalers1102 Cardiorespiratory Medicine and HaematologyOriginal Researchx-ray computedlcsh:RC705-779COPDScience & TechnologyInhalationbusiness.industrydry powder inhalersGeneral Medicinelcsh:Diseases of the respiratory systemrespiratory systemmedicine.diseaseBronchodilator AgentsDrug CombinationschemistryCorticosteroidVilanterolbusinessLife Sciences & Biomedicinelong-acting beta2 agonistmedicine.drugInternational Journal of COPD
researchProduct

A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Stud…

2020

Roland Buhl,1 Michael Dreher,2 Stephanie Korn,1 Christian Taube,3 Christian Stock,4 Christoph M Zehendner,5 Anke Kondla,5 Claus F Vogelmeier6 1Pulmonary Department, Johannes Gutenberg University Mainz, Mainz, Germany; 2Clinic of Cardiology, Pneumology, Angiology and Internal Medicine Intensive Care, University Hospital RWTH Aachen, Aachen, Germany; 3Clinic for Pneumonology, University Medicine Essen – Ruhrlandklinik, Essen, Germany; 4Biostatistics + Data Sciences Corp, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; 5HP Country Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; 6Department of Pneumology,…

medicine.medical_specialtytiotropium/olodaterolMedizinMuscarinic AntagonistsInternational Journal of Chronic Obstructive Pulmonary Disease03 medical and health scienceschemistry.chemical_compoundStudy ProtocolPulmonary Disease Chronic Obstructive0302 clinical medicineMaintenance therapySpiolto® Respimat®Internal medicineAdministration Inhalationmedicinemedia_common.cataloged_instanceCOPDHumansMulticenter Studies as Topic030212 general & internal medicineProspective StudiesEuropean unionTiotropium BromideAdrenergic beta-2 Receptor Agonistsmedia_commonCOPDbiologybusiness.industryInhalerOlodaterolGeneral MedicineLamamedicine.diseasebiology.organism_classificationLAMA/LABA/ICShumanitiesObstructive lung diseaseBenzoxazinesBronchodilator AgentsRegimen030228 respiratory systemchemistrytriple therapyDrug Therapy Combinationbusinesshormones hormone substitutes and hormone antagonistsInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Granulocyte-macrophage colony-stimulating factor (CSF) and multilineage CSF recruit human monocytes to express granulocyte CSF

1989

Abstract We assessed the capacity of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and multilineage (Multi)-CSF to induce release of granulocyte-CSF (G-CSF) by highly purified peripheral blood monocyte (Mo) preparations. Our results reveal that GM-CSF and Multi-CSF, either alone or in a synergistic concert, activate Mo to transcribe G-CSF messenger (m) RNA and release biologically active G- CSF protein into their culture supernatants. G-CSF had no regulatory effect on Mo expression of cytoplasmic G-CSF mRNA levels and G-CSF protein secretion by itself. These differential actions of CSFs provide further insight into self-regulatory mechanisms within the growth f…

medicine.medical_treatmentImmunologyGranulocyteBiologyBiochemistryMonocyteslaw.inventionColony-Stimulating FactorslawmedicineHumansRNA MessengerGrowth SubstancesCells CulturedCSF albuminCell-Free SystemGrowth factorGranulocyte-Macrophage Colony-Stimulating FactorRNABiological activityCell BiologyHematologyMolecular biologyRecombinant ProteinsDrug CombinationsGranulocyte macrophage colony-stimulating factorSecretory proteinmedicine.anatomical_structureImmunologyRecombinant DNAGranulocytesmedicine.drugBlood
researchProduct

Adalimumab in active ulcerative colitis: A “real-life” observational study

2013

Abstract Background and aims The effectiveness of adalimumab in the treatment of ulcerative colitis is under debate. Although controlled trials have shown that adalimumab is significantly better than placebo, the absolute clinical benefit is modest. We report data on the effectiveness of adalimumab in a cohort of ulcerative colitis patients treated in 22 Italian centres. Methods All patients with active disease treated with adalimumab were retrospectively reviewed. Co-primary endpoints were clinical remission at weeks 4, 12, 24 and 54. Secondary endpoints were sustained clinical remission, steroid discontinuation, endoscopic remission and need for colectomy. Results Eighty-eight patients we…

musculoskeletal diseasesAdultMaleAdalimumab “Real-life” study Ulcerative colitismedicine.medical_specialtymedicine.medical_treatmentIBDAnti-Inflammatory AgentsAdalimumab; “Real-life” study; Ulcerative colitisAntibodies Monoclonal HumanizedPlaceboCohort StudiesYoung AdultRefractoryAdrenal Cortex HormonesInternal medicineAdalimumabmedicineHumansskin and connective tissue diseases“Real-life” studyRetrospective StudiesColectomySettore MED/12 - GastroenterologiaHepatologybusiness.industryRemission InductionSettore MED/09 - MEDICINA INTERNAGastroenterologyAdalimumabmedicine.diseaseUlcerative colitishumanitiesInfliximabSurgeryDiscontinuationTreatment OutcomeUlcerative colitisCohortColitis UlcerativeDrug Therapy CombinationFemalebusinessmedicine.drug
researchProduct